Global X Cannabis
|
- Description
- Performance
- Comps
Fundamentals
Valuation
Rating
The Global X Cannabis ETF (POTX) seeks to invest in companies across the cannabis industry. This includes companies involved in the legal production, growth and distribution of cannabis and industrial hemp, as well as those involved in providing financial services to the cannabis industry, pharmaceutical applications of cannabis, CBD, or other related uses. |
Category | Global Equities |
Fund Sponsor | Global X |
Website | www.globalxfunds.com |
Inception date | Sep 18, 2019 |
Assets (mns) | $5 |
Currency | USD |
Expense ratio | 50 bp |
Distributions | Quarterly |
Regulation | Open-Ended Fund |
Custodian | |
Weighting | Market Cap |
Index replication | |
Uses derivatives | No |
Options available | No |
No. of constituents | 25 |
Wgt avg mkt cap (mns) | $217 |
Large cap (>$10bn) | 0.0% |
Mid cap ($2-10bn) | 25.4% |
Small cap (<$2bn) | 74.6% |
Developed mkts | 100.0% |
Emerging mkts | 0.0% |
CANOPY GROWTH CORPORATION | 1.5 % |
APHRIA INC | 1.4 % |
GW PHARMACEUTICALS PLC SPONSORED A | 1.4 % |
CRONOS GROUP INC | 1.2 % |
HEXO CORPORATION | 1.0 % |
CORBUS PHARMACEUTICALS HOLDINGS IN | 0.9 % |
AURORA CANNABIS INC. | 0.8 % |
MEDIPHARM LABS CORP. | 0.8 % |
TILRAY, INC. | 0.7 % |
ORGANIGRAM HOLDINGS INC | 0.7 % | Total | 10.3 % |
---|
![]() |
CANADA | 10.8 % |
![]() |
BRITAIN | 1.4 % |
![]() |
UNITED STATES | 1.1 % |
HISTORICAL PERFORMANCE 

Custom date range | Compare to | ||
thru |
Year-to-date | 1 year | 5 years | 10 years | Since Incep. |
-26.6% | -- | -- | -- | -26.6% |
versus... | Beta | R-squared |
S&P500 | -- | -- |
MSCI EAFE | -- | -- |
MSCI Emg. Mkts. | -- | -- |
Recent close | $14.83 |
30d moving avg. | $16.68 |
Annualized volatility | 0.0% |
Short interest (ETF) | 11.8% |
Relative strength (RSI) | 36 |
Avg. volume (thou.) | 23 |
Turnover | 6.6% |
Bid/Ask (% of price) | 0.88% |
ADV underlying (mns) | $270 |
FINDING ALTERNATIVE FUNDS
Below is a list of 20 potential alternatives to the Global X Cannabis ETF based on the alternatives' overlap in portfolio holdings with POTX. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.
Benchmark ticker: | POTX | Expense: | 50 bp | ALTAR Score™: | -26.1% |
Ticker | Fund Name |
Overlap1 vs POTX (%) |
Expense ratio (bp) |
Savings vs POTX (bp) |
ALTAR Score™ (%) |
ALTAR vs POTX (%) |
THCX | Cannabis | 12.8 | 70 | -20 | -5.6 | +20.5 |
MJ | ETFMG Alternative Harvest | 11.9 | 75 | -25 | -3.3 | +22.8 |
CNBS | Amplify Seymour Cannabis | 11.8 | 75 | -25 | -8.2 | +18.0 |
TOKE | Cambria Cannabis | 11.3 | 42 | 8 | 0.8 | +26.9 |
YOLO | AdvisorShares Pure Cannabis | 11.1 | 74 | -24 | -18.0 | +8.1 |
PPH | VanEck Vectors Pharmaceuticals | 1.1 | 36 | 14 | 9.4 | +35.5 |
AIIQ | AI Powered International Equity | 0.8 | 79 | -29 | 4.6 | +30.7 |
BBC | Virtus LifeSci Biotech Clinical Trials | 0.6 | 79 | -29 | -11.1 | +15.0 |
IBB | iShares NASDAQ Biotechnology | 0.4 | 47 | 3 | 0.4 | +26.5 |
SBIO | ALPS Medical Breakthroughs | 0.3 | 50 | 0 | -5.2 | +20.9 |
QCAN | SPDR MSCI Canada Quality Mix | 0.3 | 14 | 36 | 7.2 | +33.3 |
BBCA | JPMorgan BetaBuilders Canada | 0.3 | 19 | 31 | 7.2 | +33.3 |
EWC | iShares MSCI Canada | 0.3 | 47 | 3 | 7.1 | +33.2 |
ORG | Organics | 0.3 | 35 | 15 | 4.5 | +30.6 |
FLCA | Franklin FTSE Canada | 0.2 | 9 | 41 | 7.6 | +33.7 |
ISZE | iShares MSCI Int'l Developed Size Factor | 0.2 | 30 | 20 | 6.6 | +32.7 |
IPO | Renaissance IPO | 0.2 | 60 | -10 | -1.0 | +25.1 |
SCHC | Schwab Intl Small-Cap Equity | 0.2 | 12 | 38 | 6.3 | +32.4 |
VFMO | Vanguard U.S. Momentum Factor | 0.1 | 13 | 37 | 3.1 | +29.2 |
GWX | SPDR International SmallCap | 0.1 | 40 | 10 | 4.6 | +30.7 |
1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.
Content on this tab for subscribers only**
RESULTS & ESTIMATES
2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | |
---|---|---|---|---|---|---|---|
Sales per share | ** | ** | ** | ** | ** | ** | ** |
Earnings per share | ** | ** | ** | ** | ** | ** | ** |
Dividends per share ![]() |
** | ** | ** | ** | ** | ** | ** |
Book value per share | ** | ** | ** | ** | ** | ** | ** |
Sales per share growth | **% | **% | **% | **% | **% | **% | |
EPS growth | **% | **% | **% | **% | **% | **% |
Sales per share growth | **% | **% | **% | **% | **% | **% | |
EPS growth | **% | **% | **% | **% | **% | **% |
OTHER FUNDAMENTAL METRICS
Long term EPS growth est. | **% | Debt-to-equity | **x | |
Asset turnover | **% | Assets-to-equity | **x |
*Six months ago = 100 |
Content on this tab for subscribers only
VALUATION METRICS
2018 | 2019E | 2020E | |
---|---|---|---|
Price-to-sales | ** | ** | ** |
Price-to-earnings | ** | ** | ** |
Price-to-cash flow | ** | ** | ** |
Price-to-growth | ** | ** | ** |
Price-to-book value | ** | ** | ** |
Yield | ** | ** | ** |
Historical valuation trends
Forward multiple: |
Global X Cannabis | |||
Relative to: |
S&P500 | MSCI EAFE | MSCI Emg. Mkts. | Other ETF: |
AVOID |
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant. |
ALTAR Score™
|
MODERN PORTFOLIO THEORY
![]() |
CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
|